Brief: Amarin Highlights New Evidence Of Therapeutic Value Of EPA In Reducing Cardiovascular Events In At-Risk Patients Presented At ACC.23/WCC
06/03/2023 13:16
March 6 (Reuters) - Amarin Corporation PLC AMRN.O :
* AMARIN HIGHLIGHTS NEW EVIDENCE OF THERAPEUTIC VALUE OF EPA
IN
REDUCING CARDIOVASCULAR EVENTS IN AT-RISK PATIENTS PRESENTED AT
ACC.23/WCC
* AMARIN- IN VITRO DATA PRESENTATIONS SUPPORT
ANTITHROMBOTIC,
ANTIOXIDANT EFFECTS OF EPA VERSUS DHA, NO IMPACT OF MINERAL OIL
ON RATES OF LDL OXIDATION
Source text for Eikon: ID:nGNX56KV8J
Further company coverage: AMRN.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Amarin
See all newsAmarin Corporation PLC reports results for the quarter ended June 30 - Earnings Summary
Ireland's Amarin Q2 revenue falls on lower licensing payments
Amarin Corporation PLC expected to post a loss of 1 cent a share - Earnings Preview
US Supreme Court backs generic drugmaker in 'skinny label' patent case (updated)
US Supreme Court backs generic drugmaker in 'skinny label' patent case